Sprint Bioscience AB (DE:5JA1)

FRANKFURT:5JA1

5JA1

Sprint Bioscience AB

RESEARCH TOOLSreports

Sprint Bioscience AB (5JA1) Price & Analysis

0 Followers

5JA1 Stock Chart & Stats

€0.11

>-€0.01(-2.52%)

At close: Jan 08 4:00 PM EST

€0.11

>-€0.01(-2.52%)

Day’s Range― - ―

52-Week Range€0.02 - €0.38

Previous CloseN/A

Volume0.00

Average Volume (3M)83.00

Market Cap

€42.16M

Enterprise Value€352.77M

Total Cash (Recent Filing)€126.70M

Total Debt (Recent Filing)€0.00

Price to Earnings (P/E)5.5

Beta2.13

Next Earnings

Aug 26, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.83

Shares Outstanding105,515,540

10 Day Avg. Volume250

30 Day Avg. Volume83

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)1.14

Price to Sales (P/S)0.81

P/FCF Ratio1.63

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)€7.44M

Bulls Say, Bears Say

Bulls Say

Debt-free Balance SheetZero reported debt across 2021–2025 materially lowers refinancing and interest-rate risk and preserves strategic optionality. For a small biotech that relies on milestone deals, having no leverage enhances runway management, supports partner negotiations, and reduces capital structure fragility over months.

2025 Revenue And Profit InflectionA clear step-change to material revenue and positive net income in 2025 demonstrates the company's ability to convert discovery-stage assets into monetizable outcomes. This strengthens the commercial-readiness narrative and improves the credibility of future partner deal economics over the medium term.

Improved Cash GenerationA swing to strongly positive operating and free cash flow in 2025 indicates the firm can generate internal funding for discovery and selective development. Sustained positive cash conversion reduces dilution risk from new equity raises and supports longer-term program advancement and partnering leverage.

Bears Say

Volatile Earnings And Cash FlowsMaterial year-to-year swings in earnings and cash flows undermine revenue predictability and budgeting. For program-driven biotech, this volatility complicates forecasting, makes partner negotiations timing-dependent, and increases the risk that interim funding needs will arise within a 2–6 month horizon.

Historical Equity InstabilityA history of a very low equity base indicates prior funding sensitivity and potential dilution events. Even with current capitalization improved, past equity volatility suggests governance and financing have been reactive; this can pressure share-based funding needs and partner perceptions over the medium term.

Revenue Dependent On Milestone DealsBusiness model reliance on upfronts, milestones, and royalties means revenue timing is externally driven and uneven. This structural lumpiness increases cash-flow uncertainty, constrains predictable reinvestment in discovery, and makes short-to-medium term planning sensitive to partner decisions.

5JA1 FAQ

What was Sprint Bioscience AB’s price range in the past 12 months?

Sprint Bioscience AB lowest stock price was €0.02 and its highest was €0.38 in the past 12 months.

What is Sprint Bioscience AB’s market cap?

Sprint Bioscience AB’s market cap is €42.16M.

When is Sprint Bioscience AB’s upcoming earnings report date?

Sprint Bioscience AB’s upcoming earnings report date is Aug 26, 2026 which is in 67 days.

How were Sprint Bioscience AB’s earnings last quarter?

Sprint Bioscience AB released its earnings results on May 13, 2026. The company reported -€0.011 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.011.

Is Sprint Bioscience AB overvalued?

According to Wall Street analysts Sprint Bioscience AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Sprint Bioscience AB pay dividends?

Sprint Bioscience AB does not currently pay dividends.

What is Sprint Bioscience AB’s EPS estimate?

Sprint Bioscience AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Sprint Bioscience AB have?

Sprint Bioscience AB has 105,515,540 shares outstanding.

What happened to Sprint Bioscience AB’s price movement after its last earnings report?

Sprint Bioscience AB reported an EPS of -€0.011 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -7.625%.

Which hedge fund is a major shareholder of Sprint Bioscience AB?

Currently, no hedge funds are holding shares in DE:5JA1

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Sprint Bioscience AB

Sprint Bioscience AB (publ) is a pharmaceutical company focused on developing therapies for cancer and metabolic disorders. Its operations span internationally, with a presence in Sweden, across Europe, the United States, and Asia. The firm is currently advancing key drug candidates, including VPS34, which is being developed to treat various forms of cancer, and PETRA01, another prospective cancer treatment. Additionally, the company dedicates research efforts to understanding and treating conditions such as tumor metabolism and type 2 diabetes. Sprint Bioscience AB (publ) was established in 2009 and maintains its headquarters in Huddinge, Sweden.